[ad_1]
The Max Planck Institute of Neuroscience of Florida (MPFI) Announces New Labs @ Location Partnership Agreement Between MPFI's Electron Microscopy Platform (EM) and German ZEISS Microscopy Company, Recognized for Its Technologies advanced imaging. As a partner institution "labs @ location", MPFI will have access to state-of-the-art ZEISS technology prior to commercialization, providing researchers with innovative imaging tools that will enable them to search for new information about how the brain works. MPFI is the only third institution in the United States to obtain the labs @ location designation.
"ZEISS and MPFI have a long-standing relationship – we are working closely together to push the boundaries of the visualization of the ultrastructure of the brain since the creation of MPFI in 2012," said Dr. Naomi Kamasawa, head of the Ministry of Health. EM installation. "Our facilities may be small compared to other institutions, but the scientific excellence and the technology information that we have provided, as well as the continued effort and pbadion to push the boundaries of our research, have made us a privileged partner of ZEISS. "
Kirk J. Czymmek, Head of ZEISS Global Customer Centers for Microscopy, congratulated the EM laboratory in his speech, stating: "The team you have here is special and their expertise is recognized internationally."
MPFI and ZEISS launched the partnership on January 17, 2019 at an event including light correlation electron microscopy (CLEM) lectures, facility tours, as well as a signing session. and Partnership Partnership held at Dreyfoos Atrium from MPFI.
The first piece of equipment made available to MPFI scientists is known as the "FCC", which is integrated with a serial bulk scanning electron microscope system. The FCC introduces a local flow of nitrogen into the sample inside the microscope, which absorbs unwanted electrical charges that interfere with imaging. "This new technology makes it possible to obtain images of a much higher quality and allows us to collect data from even more difficult samples," explained Dr. Kamasawa. "Anything that allows us to better visualize the structure of neurons and correlate them to their function will enable us to better understand the neural networks and, ultimately, the brain itself." MPFI received FCC equipment in August of this year and was the first institution in the United States to use this technology after ZEISS made a number of significant improvements to the current commercially available model.
"The role of high-resolution imaging in resolving the functional complexity of the brain can not be overstated." This partnership demonstrates the unique expertise and research know-how of our microscopy center. It highlights the importance of connecting central centers, scientists and business partners, giving MPFI access to cutting-edge technologies to push the boundaries of neuroscience research, "said Dr. David Fitzpatrick, Scientific Director and General Manager of MPFI.
"Science is moving to the use of 3D data sets and correlative microscopy, and we are pleased to be partnering with Max Planck Florida for these purposes. we better understand the problems and benefits of our hardware and software, "said James A. Sharp, President Carl Zeiss Microscopy LLC.
###
Abdel Barraj, Sales Manager at ZEISS Microscopy North America; Kirk J. Czymmek, Head of Global ZEISS Microscopy Customer Centers; Geoff Perumal, EM / XRM specialist at Academia Life Sciences at ZEISS Microscopy; Roger Unger, Regional Sales Manager, ZEISS; Oliver Tress, Systems Specialist, 3D Imaging, ZEISS; Robert Celestine, Regional Director, MICRO OPTICS OF FLORIDA, INC.
About the Max Planck Florida Institute for Neuroscience
The Max Planck Institute of Neuroscience of Florida (MPFI), a non-profit research organization, is part of the world-renowned Max Planck Society, the most successful research organization in Germany with more than 80 institutes in the world. Since its inception in 1948, 18 Nobel laureates have emerged from the ranks of its scientists. As the first US institution, MPFI brings together outstanding neuroscientists from around the world to answer fundamental questions about brain development and function, and to develop new technologies for breakthrough scientific discoveries. Their research is publicly shared with academics, universities and other organizations around the world, providing the foundation for the development of treatments and treatments for brain disorders such as autism, schizophrenia, Parkinson's disease and Alzheimer's disease. For more information, visit http: // www.
About ZEISS
ZEISS is a leading technology company in the fields of optics and optoelectronics. The ZEISS Group develops, produces and distributes measurement techniques, microscopes, medical technologies, spectacle lenses, camera and film lenses, binoculars and semiconductor manufacturing equipment. Thanks to its solutions, the company is constantly advancing the world of optics and helping to shape technological progress. ZEISS is divided into four sectors: quality research and technology, medical technology, eye care / consumer products and semiconductor manufacturing technology. The ZEISS Group is represented in more than 40 countries and has more than 50 sales and service outlets, more than 30 manufacturing sites and around 25 R & D centers around the world.
During the fiscal year 2016/17, the company generated a turnover of about 5.3 billion euros (6.1 billion US dollars) and employs approximately 27 000 people. Founded in 1846 in Jena, the company is based in Oberkochen, Germany. Carl Zeiss AG is the strategic management holding company that manages the ZEISS Group. The company is wholly owned by the Carl Zeiss Stiftung (Carl Zeiss Foundation).
The Microscopy Group is the world's only manufacturer of optical, electronic, X-ray and ion microscopy systems, and offers correlative microscopy solutions. The portfolio includes products and services for life science and materials research, as well as for industry, training and clinical practice. The business group is based in Jena. Additional production and development sites are located in Oberkochen, Göttingen and Munich, as well as Cambridge in the United Kingdom and Peabody, MA and Pleasanton, California, USA. The group of activities is attributed to the Research and Quality Technology sector. About 6,300 employees work for this sector, generating a turnover of 1.5 billion euros during the 2016/17 financial year. Further information is available at http: // www.
Warning: AAAS and EurekAlert! are not responsible for the accuracy of the news releases published on EurekAlert! contributing institutions or for the use of any information via the EurekAlert system.
Source link
